ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma
CAR-T Therapies Will Beat T-Cell Engagers To Market
Executive Summary
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
You may also be interested in...
Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.
Pfizer DMD Gene Therapy Phase III Trial Faces A US Delay; Can Sarepta Close The Gap?
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.